162 related articles for article (PubMed ID: 19959086)
1. Standardisation of molecular monitoring for chronic myeloid leukaemia.
Cross NC
Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
[TBL] [Abstract][Full Text] [Related]
4. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
[TBL] [Abstract][Full Text] [Related]
5. [Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
Sacha T; Zawada M; Czekalska S; Florek I; Mueller M; Gniot M; Jaźwiec B; Kyrcz-Krzemień S; Leszczyńska A; Lewandowski K; Matiakowska K; Solarska I; Stokłosa T; Skotnicki AB
Przegl Lek; 2010; 67(7):454-9. PubMed ID: 21387754
[TBL] [Abstract][Full Text] [Related]
6. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in chronic myeloid leukaemia.
Cross NC
Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in chronic myeloid leukaemia patients.
Hochhaus A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):159-78. PubMed ID: 11987922
[TBL] [Abstract][Full Text] [Related]
9. Control genes in international standardization of real-time RT-PCR for BCR-ABL.
Moravcová J; Rulcová J; Poláková KM; Klamová H
Leuk Res; 2009 Apr; 33(4):582-4. PubMed ID: 18653236
[No Abstract] [Full Text] [Related]
10. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of minimal residual disease in chronic myeloid leukemia.
Faderl S; Hochhaus A; Hughes T
Hematol Oncol Clin North Am; 2004 Jun; 18(3):657-70, ix-x. PubMed ID: 15271398
[TBL] [Abstract][Full Text] [Related]
12. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.
Jennings LJ; Smith FA; Halling KC; Persons DL; Kamel-Reid S;
Arch Pathol Lab Med; 2012 Jan; 136(1):33-40. PubMed ID: 22208485
[TBL] [Abstract][Full Text] [Related]
13. Molecular methods in diagnosis and monitoring of haematological malignancies.
Yeung DT; Parker WT; Branford S
Pathology; 2011 Oct; 43(6):566-79. PubMed ID: 21881536
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
15. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
17. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
20. Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.
Hughes TP; Branford S
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S266-71. PubMed ID: 19778851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
